A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the efficacy, safety, and tolerability of multiple
doses of gemcabene 600 mg QD compared to placebo in patients with hypercholesterolemia not
adequately controlled on high-intensity or moderate-intensity stable statin therapy. Patients
with HeFH, ASCVD, or otherwise uncontrolled, may be included with baseline LDL-C value ≥ 100
mg/dL. Subjects were randomized 1:1 to gemcabene 600 mg once daily (QD) or placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Gemphire Therapeutics, Inc. NeuroBo Pharmaceuticals Inc.